Mariendistel − Leber- und Systemwirkungen

Stephan Wey

doi:10.1055/s-0041-103871

Erfahrungsheilkunde, Table of Contents

Erfahrungsheilkunde 2015; 64(4): 196-202
DOI: 10.1055/s-0041-103871

Wissen

Mariendistel − Leber- und Systemwirkungen

Stephan Wey

Abstract

Zusammenfassung

Die Mariendistel mit ihren antioxidativen, antiinflammatorischen sowie zellprotektiven Eigenschaften hat sich bisher nur bei hepatischen Indikationen durchgesetzt. Aktuelle Forschungen rücken metabolische und antikanzerogene, systemische Wirkungen in den Fokus. Klinische Studien sind dringend zu fordern, um den Platz der Mariendistel in der Immunologie und Onkologie zu klären.

Abstract

The milk thistle has antioxidant, anti-inflammatory and cell-protective effects and has been enforced only in hepatic indication. According to recent researches metabolic and anti-cancer, systemic effects come into the focus. Clinical trials are urgently required in order to clarify the place of milk thistle in immunology and oncology.

Schlüsselwörter

Mariendistel - Leber - Krebs - systemische Wirkung - antiinflammatorisch

Keywords

Milk thistle - liver - cancer - systemic action - antiinflammatory

Full Text

References

Literatur
1 Agarwal R et al. Oral milk thistle extract stops colorectal cancer stem cells from growing tumors. University of Colorado Denver: ScienceDaily; 20. April 2015
2 Albrecht M, Frerick H, Kuhn U et al. Die Therapie toxischer Leberschäden mit Legalon. Z Klin Med 1992; 47: 87-92
3 Bauer R. Institut für Pharmazeutische Wissenschaften der Karl-Franzens-Universität Graz. Pressemitteilung 15.3.2015
4 Biermer M, Berg T. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology 2009; 137: 390-391
5 Cacciapuoti F, Scognamiglio A, Palumbo R et al. Silymarin in non alcoholic fatty liver disease. World journal of hepatology 2013; 5: 109-
6 Chen PN, Hsieh YS, Chiou HL et al. Silibinin inhibits cell invasion through inactivation of both PI3KAkt and MAPK signaling pathways. Chemico-Biological Interactions 2005; 156: 141-150
7 Cheung CW, Gibbons N, Johnson DW et al. Silibinin − A Promising New Treatment for Cancer. Anti-Cancer Agents in Medicinal Chemistry 2010; 10: 186-95
8 Colombo V, Lupi M, Falcetta F et al. Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemother Pharmacol 2011; 67: 369-379
9 Comelli MC, Mengs U, Schneider C et al. Toward the definition of the mechanism of action of Silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 2007; 6: 120-129
10 Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer and Metastasis Reviews 2010; 29: 447-463
11 Enjalbert F, Rapior S, Nouguier-Soulé J et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002; 40: 715-757
12 Feher J, Deäk G, Müzes G et al. Liver-protective action of Silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989; 130: 2723-2727
13 Feher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Current pharmaceutical biotechnology 2012; 13: 210-217
14 Ferenci P, Dragosics B, Dittrich H et al. Randomized controlied trial of Silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-113
15 Ferenci P, Scherzer TM, Kerschner H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-1567
16 Flaig TW, Glode M, Gustafson D et al. A study of high dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010; 70: 848-855
17 Flaig TW, Gustafson DL, Su LJ et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007; 25: 139-46
18 Gillessen A, Herrmann WA, Kemper M et al. Einfluss von Silymarin auf Lebergesundheit und Lebensqualität. MMW − Fortschritte der Medizin 2014; 156: 120-126
19 Grüngreiff K, Albrecht M, Strenge-Hesse A. Nutzen der medikamentösen Lebertherapie in der hausärztlichen Praxis. Med Welt 1995; 46: 222-227
20 Haddad Y, Vallerand D, Brault A et al. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. : Evid Based Complement Alternat Med; 2011. nep 164
21 Hajiaghamohammadi AA, Ziaee A, Oveisi S et al. Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study. Hepat Mon 2012; 12: e6099-
22 Hoh C, Boocock D, Marczylo T et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: Silibinin levels in plasma, colorectal, and liver and their pharmacodynamic consequences. Clinical Cancer Research 2006; 12: 2944-2950
23 Huseini HF, Larijani B, Heshmat R et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 2006; 20: 1036-1039
24 Kawaguchi-Suzuki M, Frye RF, Zhu HJ et al. The effects of Milk Thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metabolism and Disposition 2014; 42: 1611-1616
25 Kumar R, Deep G, Agarwal R. An Overview of Ultraviolet B Radiation-Induced Skin Cancer Chemoprevention by Silibinin. Current Pharmacology Reports 2015; 1: 206-215
26 Lin CJ, Sukarieh R, Pelletier J. Silibinin inhibits translation initiation: implications for anticancer therapy. Mol Cancer Ther 2009; 8: 1606-1612
27 Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 2011; 17: 2288-2301
28 Qian X, Khammanivong A, Song JM et al. RNA-sequencing studies identify genes differentially regulated during inflammation-driven lung tumorigenesis and targeted by chemopreventive agents. Inflammation Research 2015; 64: 343-361
29 Rašković A, Stilinović N, Kolarović J et al. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules 2011; 16: 8601-8613
30 Riebold M, Kozany C, Freiburger L et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. : Nature Medicine; 9 February 2015
31 Saba P, Galeone F, Salvadorini F et al. Therapeutische Wirkung von Silymarin bei durch Psychopharmaka verursachten chronischen Hepatopathien. Gazz Med Ital 1976; 135: 236-251
32 Scambia G, De Vincenzo R, Ranelletti P et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer 1996; 32: 877-882
33 Singh BN, Singh HB, Singh A et al. Dietary phytochemicals alter epigenetic events and signaling pathways for inhibition of metastasis cascade. Cancer and Metastasis Reviews 2014; 33: 41-85
34 Singh RP, Agarwal R. Prostate Cancer Chemoprevention by Silibinin: Bench to Bedside. Carcinogenesis 2006; 45: 436-442
35 Solhi H, Ghahremani R, Kazemifar AM et al. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med 2014; 5: 9-12
36 Suksomboon N, Poolsup N, Boonkaew S et al. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol 2011; 137: 1328-1333
37 Ting HJ, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J 2013; 15: 707-716
38 Ting HJ, Deep G, Jain AK et al. Silibinin prevents prostate cancer cell-mediated differentiation of naive fibroblasts into cancer-associated fibroblast phenotype by targeting TGF beta2. Mol Carcinog 2014
39 To Nga NT, Tuye DT, Viet DV et al. The liver protection and antioxydant effects of silymarin extracted from milk thistle Silybum marianum (L.) Gaertn. TAP CHI SINH HOC 2014; 28: 88-92
40 Vargas-Mendoza N, Madrigal-Santillán E, Morales-González Á et al. Hepatoprotective effect of silymarin. World J Hepatol 2014; 6: 144-149
41 Vidlar A, Vostalova J, Ulrichova J et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial. Biomedical Papers 2010; 154: 239-244
42 Wellington K, Jarvis B. Silymarin; a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15: 465-489
43 Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effects and Tolerance of Silymarin (Milk Thistle) in Chronic Hepatitis C Virus Infection Patients: A Meta-Analysis of Randomized Controlled Trials. BioMed research international 2014
44 Yeh GY, Eisenberg DM, Kaptchuk TJ et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003; 26: 1277-1294